Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 30, 2021 3:38 PM 4 min read

These Healthcare Companies Are Raising Capital From Retail Investors

by Paula Tudoran Benzinga Staff Writer
Follow

These startups are providing some exciting innovations in the healthcare industry while trying to become one of the next big names in this multi-trillion dollar industry with a little help from retail investors. 

These three healthcare companies have active startup crowdfunding campaigns that are open to non-accredited investors. 

DeBioSciences

DeoBioSciences' goal is to reverse-engineer a treatment for advanced metastatic cancer in humans and pets using anecdotal data and human efficiency and safety reports obtained from bioprospecting sources.

The Company: DeoBioSciences (DBS) is a virtual biotech startup in stealth mode that aims to develop a cancer treatment created on a naturally occurring molecule that selectively kills early and advanced-stage cancer cells in humans, dogs and cats.

DeoBioSciences has created an experimental cancer medication (DBX-31) that is a potent natural anticancer molecule. The company also says it verifies research studies using molecular homologues in humans and animals that confirm the drug's safety and efficacy projections.

Furthermore, pre-clinical lab results have validated and met all of DeoBioSciences' predictions for safety and performance.

Investment Highlights: The primary objectives of this offering are to develop a synthetic form of DBX-31 for clinical usage and to test the next set of projections.

If the next trial also goes well, the company reports that its drug has a 90 percent accurate chance of eliminating 4 of the most deadly cancer forms, regardless of stage. It should also be safer, more powerful and more affordable than other cancer treatments now on the market.

  • Minimum Investment: $100
  • Valuation Cap: $15,600.000
  • Type of Security Offered: Common stock
  • Price per Share: $50
  • Platform: Netcapital

NowRx

NowRx is transforming healthcare to make it more accessible, convenient and inexpensive to everyone. The company provides patients with an end-to-end resolution for acquiring the prescriptions they need, when they need them, with same-day pharmacy delivery and telemedicine services.

The Company: NowRx is a local pharmacy that provides free same-day delivery. The firm aspires to restore healthcare to the way it should be: accessible, convenient and affordable.

NowRx provides many significant benefits to clients by leveraging a plethora of technologies, including tailored robotic dispensing, industry-leading consumer and driver apps, a proprietary pharmacy administration and logistics system.

Besides same-day delivery, the company plans to offer customers online prescribing for various conditions, automatic discount search and application, as well as insurance approval and payment assistance.

Investment Highlights: All pharmaceutical services are delivered by DEA-licensed micro fulfillment centers that use proprietary pharmacy technology and superior end-to-end robotic dispensing. These services eliminate overhead and lower dispensing costs in comparison to industry averages.

All telehealth services are delivered entirely digitally via the NowRx Telehealth app. Physicians can also use existing processes to deliver new prescriptions to NowRx.

  • Minimum Investment: $998
  • Valuation Cap: $275 million
  • Type of Security Offered: Preferred equity
  • Price per Share: $10.50
  • Platform: SeedInvest

Monogram Orthopedics

Monogram is developing an innovative surgical robot to reduce the risks of implant misplacement, fracture and subsidence, giving surgeons confidence that they can install implants that correctly suit every patient.

The Company: Monogram Orthopaedics is a medical technology business paving the way for joint reconstruction in the future. The startup is working on a product solution design that will combine 3D printing and robotics using automated digital image analysis algorithms to enable mass customization of orthopedic implants.

Monogram aims to make orthopedic care more personal by incorporating the newest discoveries of robotic, AI and 3-D printing technologies. The company's ultimate goal is to be at the forefront of the future of joint rehabilitation.

Investment Highlights: Monogram creates implants for active people who wish to improve their quality of life. The startup's integrated solution can reduce operating room costs and boost productivity by minimizing instrumentation and enhancing the cut path execution.

With the help of a robot, the startup’s been perfecting the next-generation 3D joint replacement solution. Although the underlying technologies are considered to be intricate and complex, the workflow is simple and cost-effective.

  • Minimum Investment: $250.80
  • Valuation Cap: $89.9 million
  • Offering Type: Equity
  • Type of Security Offered: Common stock
  • Price per Share: $7.50
  • Platform: StartEngine

Looking for the next big opportunity in startups? Check out this Startup Investing Hub for the latest offerings, crowdfunding campaign reviews and educational resources.

Photo by Alex Knight on Unsplash

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
StartupsAlternative investmentscrowdfundingStartEngine
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...